$0.85
0.90% today
Nasdaq, Feb 05, 04:17 pm CET
ISIN
US04962H5063
Symbol
ATOS

Atossa Genetics Inc. Stock price

$0.85
-0.11 11.82% 1M
-0.30 26.37% 6M
-0.10 10.31% YTD
+0.01 1.41% 1Y
-0.40 32.26% 3Y
-0.62 42.39% 5Y
-214.25 99.61% 10Y
Nasdaq, Closing price Tue, Feb 04 2025
-0.00 0.05%
ISIN
US04962H5063
Symbol
ATOS
Sector

Key metrics

Market capitalization $106.53m
Enterprise Value $31.65m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 1.44
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-29.49m
Free Cash Flow (TTM) Free Cash Flow $-19.57m
Cash position $74.88m
EPS (TTM) EPS $-0.21
P/E forward negative
Short interest 6.95%
Show more

Is Atossa Genetics Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,821 stocks worldwide.

Atossa Genetics Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

3 Analysts have issued a Atossa Genetics Inc. forecast:

3x Buy
100%

Analyst Opinions

3 Analysts have issued a Atossa Genetics Inc. forecast:

Buy
100%

Financial data from Atossa Genetics Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
- -
-
100%
- Direct Costs 0.03 0.03
200% 200%
-
-0.03 -0.03
200% 200%
-
- Selling and Administrative Expenses 13 13
5% 5%
-
- Research and Development Expense 16 16
2% 2%
-
-29 -29
3% 3%
-
- Depreciation and Amortization 0.03 0.03
200% 200%
-
EBIT (Operating Income) EBIT -29 -29
3% 3%
-
Net Profit -27 -27
10% 10%
-

In millions USD.

Don't miss a Thing! We will send you all news about Atossa Genetics Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Atossa Genetics Inc. Stock News

Neutral
GlobeNewsWire
about 3 hours ago
SEATTLE, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the prevention and treatment of breast cancer, extends its sincere congratulations to Dr. Tessa Cigler, esteemed Board Director at Atossa and Associate Professor of Clinical Medicine at Weill Cornell Medicine, and the Weill Corn...
Neutral
GlobeNewsWire
6 days ago
SEATTLE, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the prevention and treatment of breast cancer, today issued the following statement in response to the Patent Trial and Appeal Board's (PTAB) final written decision in PGR2023-00043 regarding U.S. Patent No. 11,572,334 (the “'33...
Neutral
GlobeNewsWire
13 days ago
SEATTLE, Jan. 23, 2025 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the prevention and treatment of breast cancer, today announced that Steven Quay, M.D., Ph.D., Chairman and CEO, has issued a Letter to Shareholders providing an update on the Company's clinical programs and recent events. The fu...
More Atossa Genetics Inc. News

Company Profile

Atossa Therapeutics, Inc. operates as a clinical-stage pharmaceutical company, which focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer and other breast conditions. It offers ForeCYTE and ArgusCYTE diagnostic tests. The ForeCYTE Breast Health Test provides personalized information about the 10-year and lifetime risk of breast cancer for women between ages 18 and 65. The ArgusCYTE Breast Health Test offers information to help inform breast cancer treatment options and to help monitor potential recurrence. The company was founded by Steven C. Quay and Shu Chih Chen in December 2008 and is headquartered in Seattle, WA.

Head office United States
CEO Steven Quay
Employees 12
Founded 2008
Website www.atossatherapeutics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today